• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Financial Services·LTA.PA
Share

Altamir Ord Stocks

€ 23.9Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

€ 987.54M

€ 23.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Altamir SCA, previously known as Altamir Amboise, is a Paris-based private equity firm established in 1995. The company employs a dual investment strategy, engaging in both direct investments and fund-of-funds, primarily targeting small and mid-cap companies. For its direct investments, Altamir concentrates on the middle market, executing buyout and growth capital transactions, and shows a particular interest in acquiring underdeveloped segments of larger corporate entities. When investing through other funds, the firm prioritizes private equity funds that specialize in growth capital and leveraged buyouts, often seeking a majority or lead shareholder position within these investments. Its sector focus is broad, encompassing healthcare, technology (including TMT and digital enterprises), various services, retail and distribution, consumer goods, and business and financial services. Within healthcare, Altamir specifically seeks out high-growth potential companies across health services (such as hospitalization, home care, and medical analysis), medical devices, niche pharmaceutical laboratories, and related areas like dermo-cosmetics, galenic development, and services/databases for health organizations. Geographically, Altamir targets unlisted companies across Europe, with a keen focus on Belgium, France, Luxembourg, Switzerland, Monaco, Italy, the Netherlands, Germany, and French-speaking European regions. It also extends its reach to North America (United States and Canada) and major emerging economies including China, India, and Brazil. For smaller and mid-sized companies, the firm prefers Continental Europe, particularly France, Italy, and the Benelux countries, while larger companies are sought across Europe, North America, and the aforementioned emerging markets. Investment sizes range from an enterprise value of €50 million to €500 million for small to mid-cap entities, and €500 million to €3,000 million for larger enterprises. Altamir makes balance sheet investments and frequently collaborates with Apax Partners France and Amboise Investissement, investing and divesting alongside them under identical terms. Furthermore, it directly invests in funds managed or advised by Apax Partners France and Apax Partners LLC. The firm typically aims for an investment horizon of five years before exiting.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of LTA.PA is 25.0 and suggests 5.04% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 02:06

The U.S. has restricted imports of humanoid robots. Which companies will be affected by this?

29.07.2026 01:14

July Could Be the Worst Month for Chipmakers' Stocks Since the Dot-Com Era

29.07.2026 00:50

eBay and its former executives will pay $56 million to settle a lawsuit alleging harassment of a couple of bloggers

28.07.2026 23:59

Gucci's sales exceeded expectations. Kering's stock soared 20%.

28.07.2026 23:23

Sales of Coca-Cola's flagship beverages hit a 17-year high thanks to the 2026 World Cup

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026